公开(公告)号：EP2440523A4

公开(公告)日：2014-03-19

申请号：EP10785754

申请日：2010-06-10

申请人： YU CHONGXI ,  TECHFIELDS BIOCHEM CO LTD

发明人： XU LINA ,  CHEN YUHUA ,  YAN BINBING ,  TU SHIQIAN ,  YU CHONGXI

IPC分类号： C07D205/12 ,  A61K31/397 ,  A61K31/43 ,  A61K31/545 ,  A61P31/00 ,  A61P31/04 ,  C07D211/16 ,  C07D211/26 ,  C07D277/60

CPC分类号： C07D499/52 ,  C07D213/76 ,  C07D215/233 ,  C07D471/04 ,  C07D499/46 ,  C07D499/62 ,  C07D499/68 ,  C07D499/74 ,  C07D499/76 ,  C07D499/86 ,  C07D501/22 ,  C07D501/24 ,  C07D501/34 ,  C07D501/36 ,  C07D501/59 ,  C07D503/18

摘要： High penetration comp1ositions (HPCs) or prodrugs (HPPs) of antimicrobials and antimicrobial-related compounds are provided. The HPCs/HPPs are capable of being converted to parent drugs or drug metabolites after crossing the biological barrier and thus can render treatments. Additionally, the HPCs/HPPs are capable of reaching areas that their parent drugs may not be able to access and rendering a sufficient concentration at the target areas and therefore render novel treatments.

摘要翻译： 提供高穿透comp1ositions（高性能计算机）或抗微生物剂和抗微生物相关的化合物的前药（HPPS）。 的HPC / HPPS能够穿越生物屏障，从而可以使处理后转化为母体药物或药物代谢物。 此外，HPC / HPPS能够到达的地区做了他们的母体药物可能无法访问，并在目标区域呈现足够的浓度，因此呈现新的治疗方法。

公开(公告)号：EP2440523A1

公开(公告)日：2012-04-18

申请号：EP10785754.2

申请日：2010-06-10

申请人： Yu, Chongxi ,  Techfields Biochem Co. Ltd

发明人： XU, Lina ,  CHEN, Yuhua ,  YAN, Binbing ,  TU, Shiqian ,  YU, Chongxi

IPC分类号： C07D205/12 ,  C07D277/60 ,  C07D211/26 ,  C07D211/16 ,  A61K31/397 ,  A61K31/43 ,  A61K31/545 ,  A61P31/00 ,  A61P31/04

CPC分类号： C07D499/52 ,  C07D213/76 ,  C07D215/233 ,  C07D471/04 ,  C07D499/46 ,  C07D499/62 ,  C07D499/68 ,  C07D499/74 ,  C07D499/76 ,  C07D499/86 ,  C07D501/22 ,  C07D501/24 ,  C07D501/34 ,  C07D501/36 ,  C07D501/59 ,  C07D503/18

摘要： High penetration comp1ositions (HPCs) or prodrugs (HPPs) of antimicrobials and antimicrobial-related compounds are provided. The HPCs/HPPs are capable of being converted to parent drugs or drug metabolites after crossing the biological barrier and thus can render treatments. Additionally, the HPCs/HPPs are capable of reaching areas that their parent drugs may not be able to access and rendering a sufficient concentration at the target areas and therefore render novel treatments.